相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial
Vera Bril et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2023)
Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy
K. Kuitwaard et al.
EUROPEAN JOURNAL OF NEUROLOGY (2021)
Subcutaneous immunoglobulin dose titration to clinical response in inflammatory neuropathy
Mahima Kapoor et al.
JOURNAL OF NEUROLOGY (2021)
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision
Peter Y. K. Van den Bergh et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2021)
Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin
Tuan Vu et al.
MUSCLE & NERVE (2021)
The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors
Marinos C. Dalakas et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)
Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study
H. P. Hartung et al.
EUROPEAN JOURNAL OF NEUROLOGY (2020)
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP PATH extension study
Ivo N. van Schaik et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2019)
Comparisons in fluctuation of muscle strength and function in patients with immune-mediated neuropathy treated with intravenous versus subcutaneous immunoglobulin
Ingelise Christiansen et al.
MUSCLE & NERVE (2018)
Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin
Giovanni Cirillo et al.
CLINICAL NEUROPHYSIOLOGY (2018)
IgPro20, the Polyneuropathy and Treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG
Melvin Berger et al.
IMMUNOTHERAPY (2018)
Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies
Jeffrey A. Allen et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2018)
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 17, pg 35, 2018)
I. N. van Schaik et al.
LANCET NEUROLOGY (2018)
Long-Term Efficacy and Safety of Hizentra (R) in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials
Stephen Jolles et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2018)
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial
Ivo N. van Schaik et al.
LANCET NEUROLOGY (2018)
Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study
L. H. Markvardsen et al.
EUROPEAN JOURNAL OF NEUROLOGY (2017)
Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial
Satoshi Kuwabara et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2017)
, Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs
Lars H. Markvardsen et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2017)
SUBCUTANEOUS VERSUS INTRAVENOUS IMMUNOGLOBULIN FOR CHRONIC AUTOIMMUNE NEUROPATHIES: A META-ANALYSIS
Juan M. Racosta et al.
MUSCLE & NERVE (2017)
Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response?
Dario Cocito et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2016)
Headache and Nausea after Treatment with High-Dose Subcutaneous versus Intravenous Immunoglobulin
Lars H. Markvardsen et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2015)
Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype
Emily K. Mathey et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction
Robert D. M. Hadden et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy
L. H. Markvardsen et al.
EUROPEAN JOURNAL OF NEUROLOGY (2014)
Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study
Dario Cocito et al.
JOURNAL OF NEUROLOGY (2014)
Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis
Carlo Lazzaro et al.
NEUROLOGICAL SCIENCES (2014)
Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy
L. H. Markvardsen et al.
EUROPEAN JOURNAL OF NEUROLOGY (2013)
Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies
Melvin Berger et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2013)
Adverse Effects of IgG Therapy
Melvin Berger
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2013)
Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy
S. Jolles et al.
CLINICAL IMMUNOLOGY (2011)
The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin
Dario Cocito et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2011)
Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study
Ingemar S. J. Merkies et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2010)
Subcutaneous immunoglobulin: opportunities and outlook
S. Misbah et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
EPIDEMIOLOGIC VARIABILITY OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY WITH DIFFERENT DIAGNOSTIC CRITERIA: STUDY OF A UK POPULATION
Yusuf A. Rajabally et al.
MUSCLE & NERVE (2009)
Incidence and prevalence of CIDP and the association of diabetes mellitus
R. S. Laughlin et al.
NEUROLOGY (2009)
EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases
I. Elovaara et al.
EUROPEAN JOURNAL OF NEUROLOGY (2008)
Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population
M. Iijima et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial
Richard A. C. Hughes et al.
LANCET NEUROLOGY (2008)
Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathy
De-Hyung Lee et al.
MUSCLE & NERVE (2008)
Idiopathic chronic inflammatory demyelinating polyneuropathy:: an epidemiological study in Italy
A. Chio et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2007)
Immunoglobulin treatment for primary antibody deficiencies - Advantages of the subcutaneous route
Ann Gardulf
BIODRUGS (2007)
Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies
Ann Gardulf et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2006)
Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies
Hubertus Koeller et al.
JOURNAL OF NEUROLOGY (2006)
MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells
XP Zhu et al.
JOURNAL OF IMMUNOLOGY (2001)
分享论文
